Fordadistrogene movaparvovec is a gene therapy treatment for people with Duchenne muscular dystrophy (DMD), manufactured by the pharmaceutical company Pfizer.
Fordadistrogene movaparvovec
Skip to section
What stage is it at?
Pfizer’s CIFFREO Phase 3 clinical trial was a global study that aimed to test if fordadistrogene movaparvovec was safe and effective for use in boys with DMD aged four to seven. On Wednesday 31 July 2024 it was announced that the trial failed to meet its primary and secondary objectives. The trial was then cancelled.
What are we doing?
We will continue to monitor for further updates.
Support and information
Duchenne muscular dystrophy
Duchenne muscular dystrophy is a muscle wasting condition caused by the lack of a protein called dystrophin. It usually affects only boys.
Research
We fund groundbreaking research to learn more about muscle wasting conditions and lead us to new treatments. We’ve already made advances that would have been unthinkable just 10 years ago, and we are determined to go even further and faster.
Our support services
We are here for everyone, but we understand that support isn’t one-size-fits-all. Speak to us. We can tailor our support to meet your unique needs.
Our helpline is open Monday-Thursday 10am-2pm.